CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
In the published model solve dated 2026-Q2, anchored at $291.50, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is priced for today's economics sustained for ~6.8 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Six of every ten revenue dollars come from Discovery and Safety Assessment, the regulated preclinical testing arm, which held a 17.7% operating margin in fiscal 2025 even as its revenue slipped 2.0% on cautious client spending [Source: FY2025 Form 10-K]. • The defining risk is written into the company's own filings: the FDA said in April 2025 it intends to expand cell-based and computational alternatives in preclinical safety studies, and the 10-K states plainly that ⟦Eliminating the use of an
Is CRL overvalued? See what's priced in →
539 institutional managers reported holding CRL in 13F filings for the quarter ended 2026-03-31. 60 opened new positions that quarter. Held by Vanguard Group, BlackRock, FMR (Fidelity), among others. On the short side, 3.6M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (5.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CRL has cut its share count 2.7% over the past five years, spending $751.35M on repurchases. It pays no dividend. Cash returned over the past three years: $688.31M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CRL over the trailing three years: 2023: 3 buys totaling $1.45M; 2025: 2 buys totaling $1.25M; 2026: 1 buy totaling $4k. 21 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CRL's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | +5.5% | -13.1% |
| 2023-11-09 | -7.3% | +26.0% |
| 2024-02-15 | +11.4% | -7.3% |
| 2024-05-10 | -3.0% | -5.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CRL's latest 8-K filings: 2026-08-05 (items 2.02, 9.01); 2026-05-11 (items 5.02, 5.07, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-02-25 (items 7.01); 2026-02-18 (items 5.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.